ASSESSMENT OF EFFICACY AND SAFETY OF ORAL FOSFOMYCIN SINGLE DOSE IN UNCOMPLICATED URINARY TRACT INFECTION AT A TERTIARY CARE HOSPITAL IN SOUTH INDIA

Objectives: Urinary tract infection (UTI) affects 150 million people worldwide each year. The rise in the UTIs is attributed to multidrug-resistant pathogens for which there are minimal treatment options available. This has facilitated the reemergence of certain old antimicrobials such as fosfomycin trometamol (FT). It seems an alternative, but the evidence towards its therapeutic efficiency is scanty. The objective of the study is to evaluate the safety and efficacy of single dose of FT in treating uncomplicated UTI and the resultant variations in the intensity of symptoms after the treatment. Methods: The study is a prospective, observational, and open-label study in the outpatient unit of the Department of General Medicine, RVM institute of Medical Sciences, for 6 months. The study comprises 50 patients among the age group of 18–70 years. Urinary Tract Infection Symptom Assessment questionnaire was used for the evaluation of symptoms pre and post treatment. After the diagnosis of uncomplicated UTI, patients were treated with single-dose of FT. Results: The study comprises 22 males and 28 females. After the treatment, there was a drastic improvement in the condition of patients. The severity level reduced and the quality of life improved post treatment and the results were statistically significant. Among 50 patients treated with the drug, 11 patients reported the side effect of diarrhea. Conclusion: Single dose oral Fosfomycin (3 g) regimen is effective in managing uncomplicated UTI with minimal side effects